We aimed to estimate the proportion of treatment-eligible people according to other professional society guidelines (appendix p 2) and describe the availability of data that would allow assessment of eligibility for hepatitis B antiviral treatment (ie, ALT, HBV DNA, cirrhosis, or liver fibrosis status) in published studies. The gene discussed is GPT; the disease is Cirrhosis.